There are currently 167 active clinical trials seeking participants for Acute Myeloid Leukemia research studies. The states with the highest number of trials for Acute Myeloid Leukemia participants are California, New York, Texas and Illinois.
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
NCT04885127
Recruiting
AML is the most common leukemia diagnosed in adults. In spite of recent low-intensity therapies that have improved outcomes for older AML patients, AML remains associated with poor prognosis as well as high symptom burden. While the benefits of early palliative care as well as electronic PROs have been well-described in the oncology population, neither have been well-studied in the AML population, and have never been studied in combination. We propose a prospective, single-center, single-arm tri... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Stanford University, Palo Alto, California
Conditions: Acute Myeloid Leukemia
Register for Updates
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
NCT03709758
Recruiting
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: Venetoclax Daunorubicin Cytarabine
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/12/2024
Locations: University of Chicago, Chicago, Illinois +1 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
NCT03622788
Recruiting
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, whit... Read More
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
02/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Register for Updates
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
NCT03810196
Recruiting
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.
Gender:
All
Ages:
25 years and below
Trial Updated:
02/12/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia
Register for Updates
Pilot Imaging Study of Leukemia
NCT03633955
Recruiting
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
Gender:
All
Ages:
Between 4 years and 80 years
Trial Updated:
02/12/2024
Locations: Children's National Health System, Washington, District of Columbia +2 locations
Conditions: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Ambiguous Lineage Leukemia or Lymphoma, Myeloma
Register for Updates
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
NCT05918692
Recruiting
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Mayo Clinic, Phoenix, Arizona +23 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia
Register for Updates
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
NCT05834244
Recruiting
To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: M.D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
NCT04358393
Recruiting
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +7 locations
Conditions: AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Register for Updates
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
NCT05672147
Recruiting
This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's or donor's blood. Then the gene fo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Register for Updates
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
NCT05139004
Recruiting
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating patients with high-risk acute leukemia or myelodysplastic syndrome. 90Y-DOTA-anti-CD25 basiliximab is a monoclonal antibody, called basiliximab, linked to a radioactive agent called 90Y-DOTA. Basiliximab attaches to CD25 positive cancer cells in a targeted way and delivers... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
01/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Register for Updates
Collecting and Storing Tissue From Young Patients With Cancer
NCT00898755
Recruiting
This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
Gender:
All
Ages:
21 years and below
Trial Updated:
01/29/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +68 locations
Conditions: Acute Lymphoblastic Leukemia, Rhabdomyosarcoma, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Soft Tissue Sarcoma
Register for Updates
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
NCT05716009
Recruiting
This is an open-label Phase Ia/Ib clinical study of tagraxofusp-erzs, a novel cytokine-drug conjugate that links interleukin-3 with a truncated diphtheria toxin, in combination with gemtuzumab ozogamicin for patients with relapsed/refractory AML. The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of tagraxofusp-erzs in combination with gemtuzumab ozogamicin in this patient population. Then, once RP2D is determined, to determine the safety and tolerability of... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/29/2024
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Acute Myeloid Leukemia
Register for Updates